Iclaprim
200px | |
Systematic (IUPAC) name | |
---|---|
(RS)-5-[(2- cyclopropyl- 7,8-dimethoxy- 2H- chromen- 5-yl) methyl] pyrimidine- 2,4- diamine | |
Clinical data | |
Routes of administration | Intravenous (oral under investigation) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Good (oral)[1] |
Identifiers | |
CAS Number | 192314-93-5 |
ATC code | J01EA03 (WHO) |
PubChem | CID 213043 |
Chemical data | |
Formula | C19H22N4O3 |
Molar mass | 354.403 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Iclaprim (INN), codenamed AR-100 and RO-48-2622, is a diaminopyrimidine dihydrofolate reductase inhibitor being developed for the treatment of complicated skin and soft tissue infections caused by antibiotic-resistant bacteria. It is structurally related to trimethoprim. In Phase III clinical trials, intravenously-administered iclaprim was found to be as effective as and better tolerated than linezolid in people with skin and soft tissue infections, many caused by methicillin-resistant Staphylococcus aureus (MRSA).[2][3] In vitro, iclaprim is highly active against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria.[1]
A new drug application for iclaprim was filed with the U.S. Food and Drug Administration in March 2008,[2] and a marketing authorisation application (MAA) was accepted by the European Medicines Agency on August 21, 2008. Phase II clinical trials are being conducted to assess whether iclaprim can be taken by mouth as well as intravenously and whether it is effective for the treatment of hospital-acquired pneumonia.[3][4]
Iclaprim has been granted fast track status by the FDA.[5]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
Further reading
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
50px | This systemic antibacterial-related article is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ 2.0 2.1 "Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections" (Press release). Reuters. March 19, 2008. http://www.reuters.com/article/pressRelease/idUS92327+19-Mar-2008+PRN20080319. Retrieved 2008-08-24.
- ↑ 3.0 3.1 "Arpida's iclaprim MAA Accepted for Review by EMEA" (Press release). PR Newswire. August 21, 2008. http://www.breitbart.com/article.php?id=prnw.20080821.UKTH008&show_article=1. Retrieved 2008-08-24.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Pages with broken file links
- Infobox drug articles with non-default infobox title
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- 2Fix
- Dihydrofolate reductase inhibitors
- Pyrimidines
- Chromenes
- Phenol ethers
- Antibiotic stubs